Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Swedish Orphan Biovitrum AB Sobi
Swedish Orphan Biovitrum AB Sobi
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Ingredients
Therapeutic: efanesoctocog alfa for haemophilia A
Haemophilia A is a rare genetic disorder in which the blood cannot clot properly; this is caused by a lack of factor VIII, one of the proteins involved in the clotting cascade
Recruitment
Sobi appoints Head of Technical Operations
Research & Development
Sobi Orfadin capsules approved in Saudi Arabia
Swedish Orphan Biovitrum's orfadin capsules approved in the Kingdom of Saudi Arabia for the treatment of hereditary tyrosinemia type 1
Estates & Facilities
Sobi opens office in Greece
The company is welcomed by those hoping for innovative therapeutic solutions in Greece
Regulatory
Sobi’s Elocta approved in Switzerland for the treatment of haemophilia A
Elocta is indicated for both on-demand and prophylaxis treatment of people with haemophilia A of all ages
Manufacturing
Sobi signs manufacturing agreements with Pfizer
Sobi is dedicated to developing and delivering innovative therapies for rare diseases
Chief Medical Officer Birgitte Volck to leave Sobi
To join GlaxoSmithKline as Head of R&D Rare Diseases
Subscribe now